Literature DB >> 18466661

Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom.

A Gauthier1, J Breuer, D Carrington, M Martin, V Rémy.   

Abstract

Recent information on epidemiology and management of herpes zoster (HZ) and post-herpetic neuralgia (PHN), a painful complication of HZ, is scarce. The objective of this study was to document the burden of HZ and PHN in the United Kingdom. This retrospective analysis of the UK General Practice Research Database aimed to estimate HZ incidence and proportion of HZ patients developing PHN and to assess management costs in immunocompetent individuals aged 50 years. A cohort of 27 225 HZ patients was selected, corresponding to an incidence of 5.23/1000 person-years. Respectively 19.5% and 13.7% of patients developed PHN at least 1 and 3 months after HZ diagnosis. Mean direct cost was pound103 per HZ patient and pound341 and pound397 per PHN episode (1- and 3-month definition respectively). Both HZ and PHN costs increased markedly with pain severity. This study confirms that HZ and PHN are frequent and costly diseases in the United Kingdom.

Entities:  

Mesh:

Year:  2008        PMID: 18466661     DOI: 10.1017/S0950268808000678

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  105 in total

1.  A pathway to leadership for adult immunization: recommendations of the National Vaccine Advisory Committee: approved by the National Vaccine Advisory Committee on June 14, 2011.

Authors: 
Journal:  Public Health Rep       Date:  2012 Jan-Feb       Impact factor: 2.792

Review 2.  Epidemiology of neuropathic pain and its impact on quality of life.

Authors:  Blair H Smith; Nicola Torrance
Journal:  Curr Pain Headache Rep       Date:  2012-06

Review 3.  Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective.

Authors:  Robert W Johnson; Marie-José Alvarez-Pasquin; Marc Bijl; Elisabetta Franco; Jacques Gaillat; João G Clara; Marc Labetoulle; Jean-Pierre Michel; Luigi Naldi; Luis S Sanmarti; Thomas Weinke
Journal:  Ther Adv Vaccines       Date:  2015-07

4.  Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland.

Authors:  Thomas D Szucs; Reto W Kressig; Manto Papageorgiou; Werner Kempf; Jean-Pierre Michel; Anton Fendl; Xavier Bresse
Journal:  Hum Vaccin       Date:  2011-07-01

5.  The burden of disease of Herpes Zoster in Tuscany.

Authors:  Miriam Levi; Irene Bellini; Leonardo Capecchi; Luca Pieri; Angela Bechini; Sara Boccalini; Silvia Callaioli; Roberto Gasparini; Donatella Panatto; Emilia Tiscione; Paolo Bonanni
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

6.  Herpes zoster and postherpetic neuralgia in Catalonia (Spain).

Authors:  Luis Salleras; Montse Salleras; Patricia Salvador; Núria Soldevila; Andreu Prat; Patricio Garrido; Angela Domínguez
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

7.  A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK.

Authors:  Lee Moore; Vanessa Remy; Monique Martin; Maud Beillat; Alistair McGuire
Journal:  Cost Eff Resour Alloc       Date:  2010-04-30

8.  Epidemiology of herpes zoster infection among patients treated in primary care centres in the Valencian community (Spain).

Authors:  Ana M Cebrián-Cuenca; Javier Díez-Domingo; María San-Martín Rodríguez; Joan Puig-Barberá; Jorge Navarro-Pérez
Journal:  BMC Fam Pract       Date:  2010-05-06       Impact factor: 2.497

9.  Impact of herpes zoster and post-herpetic neuralgia on patients' quality of life: a patient-reported outcomes survey.

Authors:  Thomas Weinke; Alexander Edte; Sonja Schmitt; Kati Lukas
Journal:  Z Gesundh Wiss       Date:  2010-03-21

Review 10.  Postherpetic neuralgia in the elderly.

Authors:  R W Johnson; J McElhaney
Journal:  Int J Clin Pract       Date:  2009-09       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.